Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with Melanoma
Jedd D. Wolchok(Cornell University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Stephanie Terzulli(Memorial Sloan Kettering Cancer Center), Rajaram Ranganathan(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Isabelle Rivière(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Melanie Heywood(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Jianda Yuan, Jian Wang(Shenyang Pharmaceutical University), Yan Zhang(Memorial Sloan Kettering Cancer Center), Alan N. Houghton(Eastern Cooperative Oncology Group), Katherine S. Panageas(Mayo Clinic), Humilidad F. Gallardo(Memorial Sloan Kettering Cancer Center), Teresa Rasalan
Cited by 107
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k